164 related articles for article (PubMed ID: 28539888)
1. Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.
Caballero I; Aira LE; Lavastida A; Popa X; Rivero J; González J; Mesa M; González N; Coba K; Lorenzo-Luaces P; Wilkinson B; Santiesteban Y; Santiesteban Y; Troche M; Suarez E; Crombet T; Sánchez B; Casacó A; Macías A; Mazorra Z
Front Pharmacol; 2017; 8():263. PubMed ID: 28539888
[TBL] [Abstract][Full Text] [Related]
2. Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study.
Barro AM; Rivero AI; Goñi AL; Navarro BO; Angarica MM; Ramírez BS; Bedoya DM; Triana CG; Rodríguez AM; Parada ÁC
Vaccine; 2012 Dec; 31(1):89-95. PubMed ID: 23142132
[TBL] [Abstract][Full Text] [Related]
3. Immuno-toxicological evaluation of her1 cancer vaccine in non-human primates: a 6-month subcutaneous study.
Mancebo Rodríguez A; Bergado Báez G; Acosta Lago E; León Goñi A; Blanco Gámez D; Fuentes Morales D; Hernández Fernández DR; Sánchez Ramírez B; Pérez Barreda A; Casacó Parada Á
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):283-290. PubMed ID: 33722157
[No Abstract] [Full Text] [Related]
4. Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.
Valdes-Zayas A; Gonzalez Z; Mulens V; Vega AM; Perez K; Lorenzo-Luaces P; Rubio MC; Estevez A; Curbelo I; Fernandez LE; Crombet T; Mazorra Z
J Immunother; 2017 Oct; 40(8):289-301. PubMed ID: 28604556
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.
Carr A; Rodríguez E; Arango Mdel C; Camacho R; Osorio M; Gabri M; Carrillo G; Valdés Z; Bebelagua Y; Pérez R; Fernández LE
J Clin Oncol; 2003 Mar; 21(6):1015-21. PubMed ID: 12637465
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.
Mulens V; de la Torre A; Marinello P; Rodríguez R; Cardoso J; Díaz R; O'Farrill M; Macias A; Viada C; Saurez G; Carr A; Crombet T; Mazorra Z; Perez R; Fernandez LE
Hum Vaccin; 2010 Sep; 6(9):. PubMed ID: 20855939
[TBL] [Abstract][Full Text] [Related]
8. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
[TBL] [Abstract][Full Text] [Related]
9. HER1-based vaccine: Simultaneous activation of humoral and cellular immune response.
Bergado Báez G; Hernández Fernández DR; Mazorra Herrera Z; Sánchez Ramírez B
Semin Oncol; 2018 Jan; 45(1-2):75-83. PubMed ID: 30318087
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
11. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.
Ramírez BS; Pestana ES; Hidalgo GG; García TH; Rodríguez RP; Ullrich A; Férnandez LE
Int J Cancer; 2006 Nov; 119(9):2190-9. PubMed ID: 16841332
[TBL] [Abstract][Full Text] [Related]
12. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
[TBL] [Abstract][Full Text] [Related]
13. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
15. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
17. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.
Nooka AK; Wang ML; Yee AJ; Kaufman JL; Bae J; Peterkin D; Richardson PG; Raje NS
JAMA Oncol; 2018 Dec; 4(12):e183267. PubMed ID: 30128502
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]